The CBD industry is widespread and very lucrative, but the FDA has sent mixed messages regarding CBD use. On the one hand, the FDA has stated that CBD is “unsafe” and not an approved additive to food, beverages and supplements; on the other hand, the FDA has not taken a single enforcement action against a company for marketing CBD-related products.

In a public hearing on May 31, 2019, the FDA gathered information in order to help develop a pathway forward to a coherent policy regarding CBDs.

In this update, we outline the takeaways from the public hearing and how clear regulatory guidelines regarding CBD products will help encourage additional investment and growth in the CBD market. Read More.